The Beacon trial is notable for a few reasons. First, it’s the first industry-sponsored, placebo-controlled study to deliver a clearly positive readout in CS. Second, the magnitude and speed of response stood out.
At 16 weeks, patients receiving brepocitinib 45 mg saw a 22.3-point mean improvement on the CSAMI-A score versus just 0.7 points on placebo, with statistically significant separation as early as Week 4. Every patient in the 45-mg arm achieved a clinically meaningful ≥10-point improvement. For context, CSAMI-A ranges from 0 to 165 and captures both disease activity and lesion severity.
On the Investigator’s Global Assessment, 69% of patients on 45 mg improved by at least two points to a score of clear or almost clear—another strong signal in a disease where disfiguring skin lesions can drive real psychosocial burden.
Even the lower 15-mg dose showed meaningful improvement, while placebo patients saw minimal benefit, reinforcing a clear drug effect and dose response.
Analysts have called the data “exceptional,” and clinicians involved described it as a “watershed moment” for a historically neglected disease. Proivant plans to move into Phase 3 after FDA discussions later this year.
With prior Phase 3 success in dermatomyositis and ongoing development in noninfectious uveitis, brepocitinib is quietly shaping up to be a very important asset in immune-mediated inflammatory disease.
Curious to see how regulators view the Phase 2 package—and whether CS could become another meaningful label expansion down the line.
Proivant Therapeutics just reported very strong Phase 2 data for brepocitinib in cutaneous sarcoidosis (CS)—a condition with no FDA-approved treatments and limited off-label options today.
#BCIC #cutaneous #sarcoidosis